

DMS

Display Date	10-19-99
Publication Date	10-20-99
Certifier	M. Bell

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

---

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

*Name of Committee:* Dermatologic and Ophthalmic Drugs Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on November 4 and 5, 1999, 8:30 a.m. to 5:30 p.m.

*Location:* Hilton Hotel, Salons A, B, and C, 620 Perry Pkwy., Gaithersburg, MD 20877, 301-977-8900.


*Contact Person:* Tracy Riley or Angie Whitacre, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12534. Please call the Information Line for up-to-date information on this meeting. Current information may also be accessed on the Internet FDA Website at [www.fda.gov](http://www.fda.gov).

*Agenda:* On November 4, 1999, during the morning session, the committee will discuss new drug application (NDA) 21-022, Loprox™ (ciclopirox nail lacquer), Hoechst Marion Roussel, Inc., for treatment of onychomycosis. On November 4, 1999, during the afternoon session, the committee will participate in a scientific discussion of clinical trial design questions for products intended

for the treatment of hand dermatitis. On November 5, 1999, during the afternoon session, the committee will discuss NDA 20-965, Levulan® (aminolevulinic acid HCL) Kerastick™ for Topical Solution, 20 percent, Dusa Pharmaceuticals, Inc., for use in the treatment of multiple actinic keratoses of the face and scalp.

*Procedure:* On November 4, 1999, from 8:30 a.m. to 5:30 p.m. and on November 5, 1999, from 1 p.m. to 5:30 p.m., the meeting will be open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions should be made to the contact person by October 29, 1999. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 9 a.m. and between approximately 1 p.m. and 1:30 p.m. on November 4, 1999. Time allotted for each presentation may be limited. Those desiring to make oral presentations should notify the contact person before October 29, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

*Closed Committee Deliberations:* On November 5, 1999, from 8:30 a.m. to 1 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)) regarding pending NDA's issues.



Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.

2).

Dated: October 12, 1999

  
\_\_\_\_\_  
Linda A. Suydam  
Senior Associate Commissioner

[FR Doc. 99-???? Filed ??-??-99; 8:45 am]

\*BILLING CODE 4160-01-F

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL

